Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited
- PMID: 8857712
- DOI: 10.1212/wnl.47.4.876
Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited
Abstract
Altered cholinergic function is a prominent feature of AD. The neuropsychological impairments of AD are attributed, at least partially, to the cholinergic disturbance, and current approaches to treatment of the cognitive abnormalities attempt to enhance cholinergic function. Behavioral changes are common in AD and include psychosis, agitation, depression, anxiety, personality alterations, and neurovegetative changes. The contribution of the cholinergic deficiency to the behavioral alterations has been little explored, but neurochemical, neuroanatomic, pharmacologic, and clinical observations suggest that the cholinergic deficiency contributes importantly to the neuropsychiatric dimension of AD. Investigation of the role of cholinergic dysfunction in the behavioral changes of AD will improve understanding of the pathophysiologic basis of these abnormalities and may lead to new types of therapy for the neuropsychiatric disturbances associated with this common dementing disorder.
Similar articles
-
The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease.Am J Geriatr Psychiatry. 1998 Spring;6(2 Suppl 1):S64-78. doi: 10.1097/00019442-199821001-00009. Am J Geriatr Psychiatry. 1998. PMID: 9581223 Review.
-
Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease.Gerontology. 1999;45 Suppl 1:15-22. doi: 10.1159/000052760. Gerontology. 1999. PMID: 9876214 Review.
-
Changes in neuropsychiatric symptoms as outcome measures in clinical trials with cholinergic therapies for Alzheimer disease.Alzheimer Dis Assoc Disord. 1997;11 Suppl 4:S1-9. Alzheimer Dis Assoc Disord. 1997. PMID: 9339266 Review.
-
Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease.Neuropsychologia. 2005;43(3):442-9. doi: 10.1016/j.neuropsychologia.2004.06.007. Neuropsychologia. 2005. PMID: 15707619
-
Cognitive and behavioral heterogeneity in Alzheimer's disease: seeking the neurobiological basis.Neurobiol Aging. 2000 Nov-Dec;21(6):845-61. doi: 10.1016/s0197-4580(00)00183-4. Neurobiol Aging. 2000. PMID: 11124429 Review.
Cited by
-
Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy.Arch Gen Psychiatry. 2011 Jan;68(1):51-60. doi: 10.1001/archgenpsychiatry.2010.184. Arch Gen Psychiatry. 2011. PMID: 21199965 Free PMC article. Clinical Trial.
-
Galantamine for the treatment of BPSD in Thai patients with possible Alzheimer's disease with or without cerebrovascular disease.Am J Alzheimers Dis Other Demen. 2008 Dec-2009 Jan;23(6):593-601. doi: 10.1177/1533317508320603. Epub 2008 Oct 9. Am J Alzheimers Dis Other Demen. 2008. PMID: 18845693 Free PMC article. Clinical Trial.
-
Clinical Heterogeneity in Alzheimer's Disease: A Possible New Amnesic Phenotype.J Alzheimers Dis Rep. 2024 Jun 21;8(1):959-969. doi: 10.3233/ADR-230196. eCollection 2024. J Alzheimers Dis Rep. 2024. PMID: 39114546 Free PMC article. Review.
-
Neuroprotection in Alzheimer's disease - new strategies for treatment.Neurotox Res. 2000;2(2-3):157-65. doi: 10.1007/BF03033791. Neurotox Res. 2000. PMID: 16787838
-
Neuropsychiatric Symptoms, Endophenotypes, and Syndromes in Late-Onset Alzheimer's Disease: Focus on APOE Gene.Int J Alzheimers Dis. 2011 Apr 7;2011:721457. doi: 10.4061/2011/721457. Int J Alzheimers Dis. 2011. PMID: 21559196 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical